Switch theme
Sign up to access all valuation multiples
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.
2012
70
LTM Revenue $29.0M
LTM EBITDA $7.0M
$90.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Magle Chemoswed Holding has a last 12-month revenue (LTM) of $29.0M and a last 12-month EBITDA of $7.0M.
In the most recent fiscal year, Magle Chemoswed Holding achieved revenue of $24.3M and an EBITDA of $6.1M.
Magle Chemoswed Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Magle Chemoswed Holding valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $29.0M | XXX | $24.3M | XXX | XXX | XXX |
| Gross Profit | $26.2M | XXX | $22.9M | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | $7.0M | XXX | $6.1M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $2.3M | XXX | $1.7M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $1.0M | XXX | $1.2M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $26.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Magle Chemoswed Holding's stock price is SEK 27 (or $3).
Magle Chemoswed Holding has current market cap of SEK 562M (or $58.0M), and EV of SEK 880M (or $90.7M).
See Magle Chemoswed Holding trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $90.7M | $58.0M | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Magle Chemoswed Holding has market cap of $58.0M and EV of $90.7M.
Magle Chemoswed Holding's trades at 3.7x EV/Revenue multiple, and 14.9x EV/EBITDA.
Equity research analysts estimate Magle Chemoswed Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Magle Chemoswed Holding has a P/E ratio of 59.2x.
See valuation multiples for Magle Chemoswed Holding and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $58.0M | XXX | $58.0M | XXX | XXX | XXX |
| EV (current) | $90.7M | XXX | $90.7M | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | 13.0x | XXX | 14.9x | XXX | XXX | XXX |
| EV/EBIT | 39.6x | XXX | 54.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 59.2x | XXX | 47.1x | XXX | XXX | XXX |
| EV/FCF | -109.8x | XXX | -31.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMagle Chemoswed Holding's last 12 month revenue growth is 27%
Magle Chemoswed Holding's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Magle Chemoswed Holding's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Magle Chemoswed Holding's rule of X is 92% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Magle Chemoswed Holding and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 59% | XXX | XXX | XXX |
| Rule of 40 | 46% | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 92% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 87% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Magle Chemoswed Holding acquired XXX companies to date.
Last acquisition by Magle Chemoswed Holding was XXXXXXXX, XXXXX XXXXX XXXXXX . Magle Chemoswed Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Magle Chemoswed Holding founded? | Magle Chemoswed Holding was founded in 2012. |
| Where is Magle Chemoswed Holding headquartered? | Magle Chemoswed Holding is headquartered in Sweden. |
| How many employees does Magle Chemoswed Holding have? | As of today, Magle Chemoswed Holding has 70 employees. |
| Is Magle Chemoswed Holding publicy listed? | Yes, Magle Chemoswed Holding is a public company listed on STO. |
| What is the stock symbol of Magle Chemoswed Holding? | Magle Chemoswed Holding trades under MAGLE ticker. |
| When did Magle Chemoswed Holding go public? | Magle Chemoswed Holding went public in 2020. |
| Who are competitors of Magle Chemoswed Holding? | Similar companies to Magle Chemoswed Holding include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Magle Chemoswed Holding? | Magle Chemoswed Holding's current market cap is $58.0M |
| What is the current revenue of Magle Chemoswed Holding? | Magle Chemoswed Holding's last 12 months revenue is $29.0M. |
| What is the current revenue growth of Magle Chemoswed Holding? | Magle Chemoswed Holding revenue growth (NTM/LTM) is 27%. |
| What is the current EV/Revenue multiple of Magle Chemoswed Holding? | Current revenue multiple of Magle Chemoswed Holding is 3.1x. |
| Is Magle Chemoswed Holding profitable? | Yes, Magle Chemoswed Holding is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Magle Chemoswed Holding? | Magle Chemoswed Holding's last 12 months EBITDA is $7.0M. |
| What is Magle Chemoswed Holding's EBITDA margin? | Magle Chemoswed Holding's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Magle Chemoswed Holding? | Current EBITDA multiple of Magle Chemoswed Holding is 13.0x. |
| What is the current FCF of Magle Chemoswed Holding? | Magle Chemoswed Holding's last 12 months FCF is -$0.8M. |
| What is Magle Chemoswed Holding's FCF margin? | Magle Chemoswed Holding's last 12 months FCF margin is -3%. |
| What is the current EV/FCF multiple of Magle Chemoswed Holding? | Current FCF multiple of Magle Chemoswed Holding is -109.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
